Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Los Angeles, California--(Newsfile Corp. - May 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 30, 2021 and August 31, 2021, inclusive (the...

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm

Intuitive Surgical

Vertex Pharmaceuticals

3 Healthcare Stocks You Can Buy and Hold for the Next Decade

Bristol-Myers

Both Bristol Myers Squibb and AbbVie spark interest for income- and value-oriented investors. You will see why we favor AbbVie as a better fit for our barbell strategy to build an enduring portfolio for an early retirement.

Bristol Myers Squibb Vs. AbbVie: Who Better Fits Our Barbell?

Altria

These stocks could be good places to park your money.

2 Dividend Kings That Are Soundly Beating the Market in 2022

Apple

Amgen

Dollar General

ProShares S&P 500 Dividend Aristocrats ETF

Schwab US Dividend Equity ETF

Western Union

The best offense is a good defense., Here are seven retirement stocks to buy that combine modest growth with safe dividends.

7 Retirement Stocks to Buy to Turbocharge Your Savings

Los Angeles, California--(Newsfile Corp. - May 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 30, 2021 and August 31, 2021, inclusive (the...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm

NORTH CHICAGO, Ill. , May 25, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022.

AbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP Reminds Investors that a Securities Fraud Class Action Lawsuit Has Been Filed Against AbbVie, Inc.

CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds Investors that a Securities Fraud Class Action Lawsuit Has Been Filed Against AbbVie, Inc.

NEW YORK , May 24, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.

ABBV LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV

The next few quarters could be a bumpy ride.

These 2 Numbers Could Spell Trouble for AbbVie Stock

- SELECT-AXIS 2 highlights the efficacy and safety data of upadacitinib (RINVOQ®) in patients with non-radiographic axial spondyloarthritis, and in patients with radiographic axial spondyloarthritis (ankylosing spondylitis) with an inadequate response to biologic disease-modifying antirheumatic drugs (bDMARDs) - SELECT-PsA 1 & 2 highlight the efficacy and safety data of RINVOQ at two years in psoriatic arthritis (PsA) patients with an inadequate response or intolerance to ≥1 non-biologic DMARD, and in PsA patients with prior inadequate response or intolerance to ≥1 bDMARD, respectively - KEEPsAKE 1 & 2 trials showcase the efficacy and safety data of SKYRIZI ® (risankizumab) in patients with active PsA NORTH CHICAGO, Ill. , May 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced accepted abstracts and presentations, including three oral presentations, three poster tours and 25 posters, at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress.

AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress

New York, New York--(Newsfile Corp. - May 23, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased AbbVie Inc. ("AbbVie") (NYSE: ABBV) between April 30, 2021 and August 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/abbvie-inc-loss-submission-form-2?prid=27629&wire=5

ABBV LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving AbbVie Inc.

NEW YORK , May 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

Raytheon Technologies

Wells Fargo

The first quarter of 2022 has signaled an end to the monetary policy-driven bull market that lasted from the Covid-19 market crash in March 2020 all the way through the end of 2021. The combination of low interest rates, heavy money-printing and easy access to corporate debt has finally made its way through the economy to cause inflation the likes of which we haven't seen since the 1980s.

Fund Managers Dump Berkshire, AbbVie in 1st Quarter

AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.

AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate

Radnor, Pennsylvania--(Newsfile Corp. - May 23, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period"). CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK...

Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm

Los Angeles, California--(Newsfile Corp. - May 23, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 30, 2021 and August 31, 2021, inclusive (the...

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm

In Study 3111-301-001, cariprazine (VRAYLAR®; 1.5mg/day) achieved the primary endpoint of statistically significant improvement on the Montgomery- Å sberg Depression Rating Scale (MADRS) total score in patients with major depressive disorder (MDD) with an inadequate response to ongoing antidepressant therapy Safety profile was consistent with that of previous studies across indications in the treatment of adults with depressive episodes associated with bipolar I disorder , the acute treatment of manic or mixed episodes associated with bipolar I disorder and schizophrenia AbbVie's supplemental New Drug Application (sNDA) for cariprazine, which includes Study 3111-301-001, is currently under review by the U.S. Food and Drug Administration (FDA) for expanded use in the adjunctive treatment of MDD with a decision expected by year-end NORTH CHICAGO, Ill. , May 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present positive data from a Phase 3 trial of cariprazine (VRAYLAR®; 1.5mg/day), Study 3111-301-001, for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant therapy.

AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting

NEW YORK , May 23, 2022 /PRNewswire/ -- Attention AbbVie Inc. ("AbbVie") (NYSE: ABBV) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 30, 2021 and August 31, 2021. If you suffered a loss on your investment in AbbVie, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind AbbVie Investors of a Lead Plaintiff Deadline of June 6, 2022

CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1-3 Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients4-6 If approved by the European Commission (EC), this would be upadacitinib's fifth therapeutic indication in the EU The EC decision is anticipated in the third quarter of 2022 NORTH CHICAGO, Ill. , May 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis

New York, New York--(Newsfile Corp. - May 21, 2022) -  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the "Class Period"), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

ROSEN, Top Ranked Investor Counsel, Encourages AbbVie Inc. Investors to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV

Clorox

Chevron

Merck

Procter & Gamble

Visa

Exxon Mobil

While the current market environment is full of uncertainty, these dividend stocks to buy offer a hedge against the rampant inflation rates. The post 7 Quality Dividend Stocks to Buy on the Dip appeared first on InvestorPlace.

7 Quality Dividend Stocks to Buy on the Dip

American Electric Power Company

Brookfield Infrastructure

Duke Energy

Philip Morris

Although the recent market choppiness has many folks worried, you can still depend on these relevant retirement stocks to buy. The post 7 Retirement Stocks to Buy for Any Market Conditions appeared first on InvestorPlace.

7 Retirement Stocks to Buy for Any Market Conditions

Los Angeles, California--(Newsfile Corp. - May 20, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 30, 2021 and August 31, 2021, inclusive (the...

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm

If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs Submission is supported by Phase 3 study that demonstrated patients had significant increases in hours of "On" time without troublesome dyskinesia, compared to oral immediate-release carbidopa/levodopa NORTH CHICAGO, Ill. , May 20, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD).

AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease

News for AbbVie Stock (ABBV)